In Australia, Revlimid (lenalidomide) has received marketing authorization approval from the Australian Therapeutic Goods Administration (TGA) for use in combination with dexamethasone as a treatment for patients with
The suit was filed in the US District Court in Newark, New Jersey. The suit claims the companies have known since 2006 that the combination of drugs was
The Data Safety Monitoring Board (DSMB) has conducted a safety analysis of defibrotide as part of the interim analysis and concluded that there are no safety concerns at
The company has asked the FDA for permission to initiate a clinical trial of the Zenith Branch Endovascular Graft-Iliac Bifurcation with the H&L-B One Shot Introduction System at
Pending the SFDA’s review of conformity to product standard documents and labeling to applicable regulations, the application will progress to the concluding administrative approval. The Aware HIV-1/2 OMT
Under the terms of the agreement, Quantum Genomics (QGC) retains the right to acquire the intellectual property generated by Inserm and to exploit associated know-how. QGC will fund
In addition, Orexigen has granted the underwriters a 30-day option to purchase an additional 1.05 million shares to cover overallotments, if any. Merrill Lynch & Co. acted as
The new products, the Trinity Biotech EU Lyme IgG + VlsE EIA and the EU Lyme IgM EIA are designed for use as screening assays in clinical laboratories.
The agreement will cover technology transfer, scale-up, and validation of the manufacturing process for TNFerade through cGMP consistency lots that will be produced at Cobra’s facility in Oxford,
Under the agreement which has been extended for a further three years, GlaxoSmithKline (GSK) and the TB Alliance jointly fund 15 to 25 fully dedicated scientists at GSK’s
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.